T1	intervention 138 175	gonadotropin-releasing hormone (GnRH)
T2	condition 212 243	chemotherapy-induced amenorrhea
T3	eligibility 247 322	young breast cancer patients undergoing cyclophosphamide-based chemotherapy
T4	No-of-participants 324 335	One hundred
T5	eligibility 336 382	hormone-insensitive breast cancer participants
T6	average-age 389 400	18-40 years
T7	location 468 473	Egypt
T8	No-of-participants 568 573	Fifty
T9	outcome-Measure 1085 1150	Resumption of menstruation at 12 months after end of chemotherapy
T10	outcome-Measure 1176 1201	Postchemotherapy hormonal
T11	outcome-Measure 1206 1224	ultrasound changes
T13	control 643 661	chemotherapy alone
T14	intervention-value 1435 1438	80%
T16	control-value 1544 1547	80%
T17	intervention-value 1552 1555	84%
T12	outcome 1328 1357	menstruation resumption rates
T18	outcome 1666 1697	hormonal and ultrasound markers
